3 Dazzling Dividend Stocks for Your Portfolio Now

Generado por agente de IAEli Grant
domingo, 1 de diciembre de 2024, 5:59 am ET1 min de lectura
ABBV--
LLY--


Are you looking for dividend stocks that offer a combination of high yields, steady growth, and attractive valuations? Look no further. We've compiled a list of three fantastic dividend stocks that you should consider buying sooner rather than later.


Dividend Stocks


1. AbbVie (ABBV) - A Dividend King with a Bright Future
AbbVie is a pharmaceutical company that has increased its dividend for 52 consecutive years, qualifying it as a Dividend King. With a forward dividend yield of nearly 4.5%, AbbVie offers an appealing income stream. The company's future growth is driven by its upcoming drugs Rinvoq and Skyrizi, which are expected to exceed Humira's peak annual sales by 2027. Despite AbbVie's dismal stock performance this year, its forward earnings multiple of only 12.5x suggests that it may be undervalued.

2. Eli Lilly (LLY) - A Biopharmaceutical Giant with Growing Potential
Eli Lilly has gained attention this year due to its work in the diabetes and weight loss markets. The company's obesity drugs are expected to see significant growth through the end of the decade, providing a substantial tailwind for the company. Eli Lilly's entire lineup and pipeline are impressive, and its dividend track record is equally compelling. With a forward dividend yield of 0.76% and an impressive 75% increase in dividends over the past five years, Eli Lilly is an excellent choice for income seekers.

3. Gilead Sciences (GILD) - A High-Yield Dividend Stock with Strong Fundamentals
Gilead Sciences offers a dividend yield of 4%, more than double the S&P 500 average of 1.6%. The company has been increasing its dividend regularly over the years, with a 32% increase in its dividend over the past five years. Gilead's solid HIV business and fast-growing oncology segment, driven by Trodelvy, are expected to continue driving growth. The company's modest payout ratio of 64% also implies room for future dividend hikes. At a forward price-to-earnings multiple of less than 11, Gilead is a relatively cheap buy.



In conclusion, AbbVie, Eli Lilly, and Gilead Sciences offer attractive dividend yields, strong growth prospects, and favorable valuations. By investing in these three fantastic dividend stocks now, you can take advantage of their current income streams and potential for long-term growth. Keep an eye on these companies as they continue to deliver impressive results and reward shareholders with rising dividends.
author avatar
Eli Grant

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios